Evgen Pharma said Tuesday it had recruitment the final patient in its stroke treatment trial and added that the last patient had completed its breast cancer trial without disease progression.
The company said it had recruited the final patient for its SAS Phase II trial for SFX-01, a proposed treatment that tackles subarachnoid haemorrhage treatment, a rate type of stroke.
The read-out of the primary endpoints of the trial were expected to released in second quarter of 2019, in-line with market expectation. The secondary endpoints, which included the assessment of patients' cognitive function at three and six months post haemorrhage, would be read-out in late summer 2019.
The primary objectives of SAS trial relate to safety, tolerability and blood flow as measured by Transcranial Doppler (TCD) ultrasound.
The company also announce that the last patient recruited to the STEM trial assessing the company's metastatic breast cancer treatment had reached the 24-week end-point without disease progression.
The STEM trial was an open label, multi-centre, Phase IIa trial of patients with ER+ metastatic breast cancer who had been on treatment with tamoxifen, aromatase inhibitors or fulvestrant, the company said. All patients had previously responded to their hormone therapy but then presented with progressive disease, demonstrating the start of resistance.
'An encouraging interim review of the STEM trial data was announced on 11 June 2018 and the Company continues to expect the final data read-out in the latter part of Q1 2019,' it added.
At 10:29am: (LON:EVG) Evgen Pharma Plc share price was +0.75p at 16.5p